Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 401 publications.

Falope O, Nyaku MK, O'Rourke C, Hermany LV, Plavchak B, Mauskopf J, Hartley L, Kruk ME. Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs. Expert Rev Vaccines. 2022 Sep 5. doi: 10.1080/14760584.2022.2116007

Kawai AT, Fuller CC, de Luise C, Layton JB, Johannes CB, Brown J, Platt R, Gilsenan AW. Adapting to the dynamic landscape of the COVID-19 pandemic: proposed study design approaches for a postauthorization safety study for Pfizer-BioNTech COVID-19 vaccine in the United States. Presented at the 2022 ICPE Conference; August 28, 2022. Copenhagen, Denmark.

Seeger JD, Jonsson Funk M, Bradley Layton J, Lloyd P. Considerations of misclassification and confounding on COVID-19 vaccines effectiveness studies - a Vaccine SIG endorsed symposium. Presented at the 2022 ICPE Conference; August 26, 2022. Copenhagen, Denmark.

Polo R, Garcia-Albeniz X, Teran C, Morales M, Rial-Crestelo D, Garcinuno MA, Garcia del Toro M, Hita C, Gomez-Sirvent JL, Buzon L, Diaz de Santiago A, Perez Arellano JL, Sanz J, Bachiller P, Martinez Alfaro E, Diaz-Brito V, Masia M, Hernandez-Torres A, Guerra J, Santos J, Arazo P, Munoz L, Arribas JR, Martinez de Salazar P, Moreno S, Hernan MA, del Amo J. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. Clin Microbiol Infect. 2022 Aug 5. doi: 10.1016/j.cmi.2022.07.006.

Fuller CC, Kawai AT, Haynes K, Coughlin K, Reynolds JS, Hawrusik R, Horgan C, Calingaert B, Johannes CB, Bradley Layton J, Peterson A, Praet N, Willame C, Yost E, Brannan C, McMahill-Walraven CNN, Guzman M, Jamal-allial A, Nair V, Seals RM, Wang FT, Selvan M, MA Q, Platt R, Gilsenan AW, Brown J. Capacity for identifying Janssen Ad26.COV2.S COVID-19 vaccination in four US health insurance and state Immunization Information System databases: preparation for a post authorization safety study. Presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Weibel D, Sturkenboom M, Eijkemans R, van den Bor R, Elbers R, Plana E, Garcia de ALbeniz X, Weinrib R, Yefimenko N, Bianchini E, Stona L, Poblador-Plou B, Swart-Polinder K, Bartolini C, Hyeraci RG, Roy D, Lupattelli A, Villalobos F, Barbieri E, Garg RK, Rubino H, de Luise C, Arana A. VAC4EU active safety surveillance study of the BNT162b2 COVID-19 vaccine in five European countries: study design and first results. Presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Garcia de ALbeniz X, Polo R, Teran C, Morales M, Rial-Crestelo D, Garcinuno MA, Garcia del Toro M, Hita C, Gomez-Sirvent JL, Buzon L, Diaz de Santiago A, Perez JL, Sanz J, Bachiller P, Martinez E, Diaz-Brito V, Masia M, Hernandez-Torres A, Guerra J, Arazo P, Arribas J, Martinez de Salazar P, Moreno S, Hernan MA, del Amo J. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. A randomized clinical trial. Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.

Romano C, Fehnel S, Stoddard J, Sadoff J, Lewis S, McNulty P, Chan EKH, Evans E, Jamieson C, Slagle AF, Mangel A, McQuarrie K. Development of a novel patient‑reported outcome measure to assess signs and symptoms of COVID‑19. J Patient Rep Outcomes. 2022 Jul 29;6(1):85. doi: 10.1186/s41687-022-00471-w

Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch D. Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Jun 29;10(3):e0042522. doi: 10.1128/spectrum.00425-22

Oglesby A, Davis AE, Mellott CE, Fraysse J, Swygard H, Brogan A. Estimating the number of individuals needed to treat with different pre-exposure Prophylaxis options to avoid 1 new HIV-1 infection in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Davis A, Brogan A, Mellott CE, Fraysse J, Oglesby A. Cost-effectiveness of every two month Cabotegravir long-acting (CAB-LA) compared with daily oral Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) for pre-exposure Prophylaxis (PrEP) to prevent HIV-1 infection in the United States. Presented at the ISPOR 2022 Conference; May 10, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Yi Z, Graham J, Diaz-Decaro J, Myers E, Buck P. The public health impact of routine vaccination in 16-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Jacobson EU, Hicks KA, Carrico J, Purcell DW, Green TA, Mermin JH, Farnham PG. Optimizing HIV prevention efforts to achieve EHE incidence targets. J Acquir Immune Defic Syndr. 2022 Apr;89(4):373-80. doi: 10.1097/QAI.0000000000002885

Poirrier JE, DeMartino JK, Nagar S, Carrico J, Hicks K, Meyers J, Stoddard J. Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. Hum Vaccin Immunother. 2022 Apr 1;1-11. doi: 10.1080/21645515.2022.2040328

Chen YH, Farnham PG, Hicks KA, Sansom SL. Estimating the HIV effective reproduction number in the United States and evaluating HIV elimination strategies. J Public Health Manag Pract. 2022 Mar;28(2). doi: 10.1097/PHH.0000000000001397

Osborne R, Nelson L, Fehnel S, Williams N, Bender RH, Ziemiecki R, Gymnopoulou E, De Paepe E, Norcross L, Heijnen E, Ispas G, Cheret A, Comeaux C, Callendret B, Vandendijck Y, Chan E, Scott J. Measurement of symptoms in respiratory syncytial virus–infected adults: meaningful within-patient change thresholds for the respiratory infection intensity and impact questionnaire (RiiQ). Poster presented at the 8th ESWI Influenza Conference Scientific and SPI Virtual Programme; December 4, 2021.

Bisanzio D, Davis AE, Talbird SE, Van Effelterre T, Metz L, Mathieu VO, Brogan AJ. Individual-based modeling of Ebola outbreaks in the DRC to assess the impact of preventive vaccination strategies. Poster presented at the 8th International Conference on Infectious Disease Dynamics; November 30, 2021. Bologna, Italy.

Curran D, Patterson B, Carrico J, Salem A, La E, Lorenc S, Hicks K, Poston S, Carpenter C. Cost-effectiveness analysis of recombinant Zoster vaccine for the prevention of herpes Zoster in immunocompromised adults diagnosed with select cancers in the United States. Poster presented at the 2021 Lymphoma and Myeloma (L&M) Virtual Congress; October 2021. [abstract] Am J Hematol. 2021 Oct 15; 96(S1):S26. doi: 10.1002/ajh.26351

Curran D, Patterson BJ, Carrico J, Salem AE, La EM, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for vaccinating immunocompromised adults against herpes zoster in the United States. Poster presented at the IDWeek 2021 Virtual Conference; September 29, 2021.

Han E, Lu E, Heyes A, Mauskopf J, Bracher M, Birch H. Common symptoms in hospitalized COVID-19 patients by age, severity and survival outcome – A literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Han E, Lu E, Heyes A, Mauskopf J, Birch H, Bracher M. The use of pharmacological therapies in hospitalized COVID-19 patients – a literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Lu E, Han E, Heyes AE, Mauskopf J, Bracher MG, Birch HJ. Economic burden associated with clinical management of COVID-19 – a literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Danysh HE, Gilsenan A, Arana A, Pladevall-Vila M, Layton JB, Ziemiecki R, Chen H, Hunt PR, Johannes C. Validation of acute outcomes among patients with type 2 diabetes mellitus in the clinical practice research datalink. Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Layton JB, Ziemiecki R, Danysh HE, Gaber C, Gilsenan A, Johannes CB. Graphical representation of an array of quantitative bias analysis scenarios for differential outcome misclassification. Presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Layton JB, Ziemiecki R, Danysh H, Gilsenan A, Johannes C. Graphical representation of multiple quantitative bias analysis scenarios for unmeasured confounding. Poster presented at the Virtual ICPE 2021 Conference; August 23, 2021.

Patterson BJ, Myers K, Stewart A, Mange B, Hillson EM, Poulos C. Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment. Expert Rev Vaccines. 2021 Jul 22. doi: 10.1080/14760584.2021.1910502

Bryan A, Earnshaw SR, McDade C, Ines M, Micallef C, Enoch DA. Economic evaluation of diagnostic-driven versus empirical treatment strategies in high-risk immunocompromised patients with suspected Aspergillus infection. Poster presented at the 2021 Virtual 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); July 9, 2021.

Johannes C, Layton JB, Beachler DM, Ziemiecki RM, Li L, Danysh HE, Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A. Risk of acute kidney injury in real-world use of dapagliflozin. Presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.

Johannes C, Layton JB, Beachler DC, Ziemiecki RM, Li L, Danysh HE, Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A. Risk of severe complications of urinary tract infection in real-world use of dapagliflozin. Poster presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.

Vinceti M, Filippini T, Rothman KJ, Di Federico S, Orsini N. SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy. Environ Res. 2021 Jun;197:111097. doi: 10.1016/j.envres.2021.111097

Patterson BJ, Buck PO, Curran D, Van Oorschot D, Carrico J, Herring WL, Zhang Y, Stoddard JJ. Estimated public health impact of the recombinant zoster vaccine. Mayo Clin Proc Innov Qual Outcomes. 2021 May 26;5(3):596-604. doi: 10.1016/j.mayocpiqo.2021.03.006

Osborne RH, Nelson L, Elsworth GR, Fehnel S, Williams N, Bender RH, Ziemiecki R, Gymnopoulou E, De Paepe E, Norcross L, Heijnen E, Ispas G, Cheret A, Comeaux C, Chan E, Scott JA. Psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire Version 2 (RiiQÂ™v2) symptom scores for respiratory syncytial virus. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.

La E, Poston S, Curran D, Lorenc S, Salem AE, Carrico J, Hicks KA, Anderson S, Carpenter CF. Cost-effectiveness analysis of recombinant zoster vaccine for vaccinating immunocompromised adults against Herpes Zoster in the United States. Presented at the ACIP Herpes Zoster Working Group; April 2021. Atlanta, GA.

Brogan AJ, Talbird SE, Davis AE, La EM, Kumar PN. The cost-effectiveness and budget impact of ibalizumab-uiyk for adults with multidrug-resistant HIV-1 infection in the United States. Pharmacoeconomics. 2021 Apr;39(4):421-32. doi: 10.1007/s40273-020-00992-6

Hicks KA, Ghaswalla P, Carrico J, Anderson S, Novy P, Hogea C, Hayney MS. Estimations of the cost of university-based outbreaks of serogroup B meningococcal disease in the United States. Poster presented at the Pediatric Academic Societies (PAS) 2021 Virtual Meeting; April 2021.

Jacobson E, Hicks KA, Carrico J, Purcell D, Green T, Mermin J, Farnham P. Optimizing HIV prevention efforts to achieve EHE incidence targets. Presented at the 2021 Virtual Conference on Retroviruses and Opportunistic Infections (CROI); March 6, 2021.

Sansom SL, Hicks KA, Carrico J, Jacobson EU, Shrestha RK, Green TA, Purcell DW. Optimal allocation of societal HIV prevention resources to reduce HIV incidence in the United States. Am J Public Health. 2021 Jan;111(1):150-8. doi: 10.2105/AJPH.2020.305965

Mauskopf J, Masaquel C, Huang L. Evaluating vaccination programs that prevent diseases with potentially catastrophic health outcomes: how can we capture the value of risk reduction? Value Health. 2021 Jan 1;24(1):86-90.

Qin S, Nelson L, McLeod L, Ma J, López Sánchez B, Gamil M, Stevens M, Jane Scott J. Psychometric evaluation of the pediatric RSV severity and outcomes rating system version 7 (PRESORSv7.1, observer-reported and PRESORSv7 clinician- reported forms) scores in young children hospitalized with respiratory syncytial virus infection. Presented at the 2021 Virtual Visual ISOQOL 28th Annual Conference; October 12, 2021. [abstract] Qual Life Res. 2021; 30(Suppl 1):S16-7. doi: https://doi.org/10.1007/s11136-021-02976-1

Huang L, Mauskopf J, Farkouh R, Masaquel C. Use of cost-effectiveness analyses for decisions about vaccination programs for meningococcal disease in the United States, United Kingdom, The Netherlands, and Canada. Expert Rev Vaccines. 2021 Jan;20(1):59-72. doi: 10.1080/14760584.2021.1878030

Njue A, Coyne C, Margulis AV, Wang D, Marks MA, Russell K, Das R, Sinha A. The role of congenital cytomegalovirus infection in adverse birth outcomes: a review of the potential mechanisms. Viruses. 2020 Dec 24;13(1):E20. doi: 10.3390/v13010020

Heyes AE, Nuabor WA, Costello JJ, Mauskopf JM, Petitiean A, Andrew MK. Posthospitalisation outcomes in older patients hospitalised for influenza: a comprehensive literature review. Poster presented at the 2020 Virtual 7th ESWI Influenza Conference; December 6, 2020.

Patterson BJ, Herring WL, Van Oorschot D, Curran D, Carrico J, Zhang Y, Ackerson BK, Bruxvoort K, Sy LS, Tseng HF. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. J Manag Care Spec Pharm. 2020 Dec;26(12):1567-75. doi: 10.18553/jmcp.2020.20251

Poirrier J-E, Carrico J, DeMartino JK, Hicks KA, Stoddard JJ, Nagar S, Meyers J. The potential for reducing opioid and analgesic prescriptions via herpes zoster vaccination. Poster presented at the IDWeek 2020 Virtual Conference; October 21, 2020.

Layton JB, McGrath LJ, Sahrmann JM, Ma Y, Dharnidharka VR, O'Neil C, Weber DJ, Butler AM. Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Layton JB, McGrath LJ, Sahrmann JM, Dharnidharka VR, O'Neil CA, Butler AM. Plotting daily incidence of influenza vaccine reactions among patients with end-stage renal disease to inform study design decisions. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Layton JB, Zhou CK, Danysh HE, Bleachler DC, Ziemiecki R, Dinah J, Yin R, Calingaert B, Hunt PR, Gilsenan AW, Johannes CW. Identifying cohorts of patients with type 2 diabetes mellitus initiating dapagliflozin in three data sources. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Dinh J, Danysh HE, Johannes C, Gutierrez L, Schmid R, Arana A, Kaye JA, Pladevall-Vila M, Garcia de ALbeniz X, Hunt PR, Gilsenan A, Beachler DC, Ke Zhou C. Description of acute kidney injury and breast cancer outcome validation processes across three databases. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

McGrath LJ, Layton JB, Sahrmann JM, Dharnidharka VR, OʼNeil CA, Butler AM. Utilization of a booster dose of influenza vaccine among adults with end-stage renal disease in the United States. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Danysh HE, Layton B, Beachler DC, Arana A, Pladevall-Vila M, Schmid R, Calingaert B, Ziemiecki R, Hunt PR, Gilsenan A, Johannes C. Validation of acute outcomes among patients with type 2 diabetes mellitus in Medicare: a pilot study. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 2020.